Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor

Imatinib, an orally administered protein-tyrosine kinase inhibitor (TKI) is indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Severe hepatotoxicity associated with imatinib is rare, and relationship to polymorphism of uridine diphosphate glucuro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Gastroenterol
Main Authors: Saif, Muhammad Wasif, Smith, Melissa Hennessey, Maloney, Antonia, Diasio, Robert B.
Formato: Artigo
Idioma:Inglês
Publicado em: Hellenic Society of Gastroenterology 2016
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5049570/
https://ncbi.nlm.nih.gov/pubmed/27708529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2016.0053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados